Bruselloz hastalarında serum YKL-40 düzeylerinin belirlenmesi

Abstract

Amaç: Bruselloz tanılı hastalarda serum YKL-40 düzeylerini belirlemek.

Gereç ve Yöntemler: Bu çalışmaya serum aglütinasyon testi pozitif 40 Bruselloz hastası ve 41 sağlıklı kontrol grubu dahil edilmiştir. İki grup arasında serum YKL-40, hematolojik parametreler ve C reaktif protein (CRP) değerleri karşılaştırılmıştır.

Bulgular: Bruselloz hasta grubunda, YKL-40 değeri 15.0 ± 8.8 ng/mL, CRP 0.2 ± 0.1 mg/dL, Nötrofil/ Lenfosit oranı (NLR) 1.5 ± 1.0 ve Platelet/Lenfosit oranı (PLR) 109.3 ± 46.4 idi. Kontrol grubunda, YKL-40 değeri 12.7 ± 6.1ng/mL, CRP 1.48 ± 2.1mg/dL, Nötrofil/ Lenfosit oranı (NLR) 2.1 ± 0.7 ve Platelet/Lenfosit oranı (PLR) 147.8 ± 59.0 idi.

Sonuç: YKL-40 düzeylerinde hasta ve kontrol grubu arasında anlamlı bir fark bulunmamıştır. Hasta grubunda kontrol grubuna göre CRP anlamlı olarak yüksek, bunun yanında YKL-40 ile CRP, PLT, PLR, NLR ve yaş arasında pozitif korelasyon saptanmıştır. Ancak YKL-40’ ın enfeksiyon hastalıklarında rolünün daha iyi anlaşılabilmesi için ileri çalışmalara ihtiyaç vardır.

Keywords

• Bruselloz,YKL-40,infeksiyon

Determination of serum YKL-40 levels in patients with brucellosis

Abstract

Aim: To determine serum YKL-40 levels in patients diagnosed with brucellosis.

Material and Methods: This study included 40 Brucellosis patients with positive serum agglutination tests and 41 healthy control subjects. The two groups were compared with regard to their serum YKL-40, hematological parameters, and C-reactive protein (CRP) values.

Results: The brucellosis patient group presented YKL-40 values of 15.0 ± 8.8 ng/mL, CRP values of 0.2 ± 0.1 mg/dL, a Neutrophil/Lymphocyte ratio (NLR) of 1.5 ± 1.0, and a Platelet/Lymphocyte ratio (PLR) of 109.3 ± 46.4. The control group presented YKL-40 values of 12.7 ± 6.1ng/mL, CRP values of 1.48 ± 2.1mg/dL, a Neutrophil/Lymphocyte ratio (NLR) of 2.1 ± 0.7, and a Platelet/Lymphocyte ratio (PLR) of 147.8 ± 59.0.

Conclusion: No significant differences were determined between the YKL-40 levels of the patient and control groups. The patient group manifested significantly higher levels of CRP compared to the control group, and YKL-40 was determined to be positively correlated with CRP, PLT, PLR, NLR and age. However, further studies are needed for the role of YKL-40 in infectious diseases to be understood more clearly.

Keywords

• brucellosis,YKL-40,diagnostic value

References

1. 1. EJ Y. Brucella species. In: Mandell GL, Bennet JE, Dolin R, (eds). Principles and Practice of Infectious Diseases. 6th ed. New York: Churchill Livingstone, 2005: 2669-72.
2. 2. Hussein MZ, Abou-Elnoeman SA, Al-Fikky AA, El-Samadouny EI, Shaaban AAM. Evaluation of Rose Bengal Test, Standard Tube Agglutination Test and Nested PCR for the diagnosis of Human Brucellosis. Egypt J Med Microbiol 2006; 15: 249-56.
3. 3. Seleem MN, Boyle SM, Sriranganathan N. Brucellosis: a re-emerging zoonosis. Vet Microbiol 2010; 140: 392-8.
4. 4. Galinska EM, Zagorski J. Brucellosis in humans-etiology, diagnostics, clinical forms, Ann Agric Environ Med 2013; 20: 233–38.
5. 5. Hekmatimoghaddam S, Sadeh M, Khalili MB, Mollaabedin M, Sazmand A. Comparison of PCR, Wright agglutination test and blood culture for diagnosis of brucellosis in suspected patients. Pak J Biol Sci 2013; 16: 1589–92.
6. 6. Gomez MC, Nieto JA, Rosa C, Geijo P et al. Evaluation of seven tests for diagnosis of human brucellosis in an area where the disease is endemic. Clin Vaccine Immunol 2008; 15: 1031-33.
7. 7. Asaad AM, Alqahtani JM. Serological and molecular diagnosis of human brucellosis in Najran, Southwestern Saudi Arabia. J Infect Public Health 2012; 5: 189-94.
8. 8. Olt S, Ergenc H, Acikgoz SB. Predictive contribution of neutrophil/lymphocyte ratio in diagnosis of brucellosis. Biomed Res Int 2015; 2015: 210502.

9. 9. Łata E, Gisterek I, Matkowski R, Szelachowska J, Kornafel J. The importance of determining the prognostic marker YKL-40 in serum and tissues. Pol Merkur Lekarski 2010; 28: 505-8.
10. 10. Roslind A, Johansen JS. YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation. Methods Mol Biol 2009; 511: 159-84.
11. 11. Libreros S, Iragavarapu-Charyulu V. YKL-40/CHI3L1 drives inflammation on the road of tumor progression. J Leukoc Biol 2015; 98: 931-36.
12. 12. Faibish M, Francescone R, Bentley B, Yan W, Shao R. A YKL-40- neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol Cancer Ther 2011; 10: 742-51.
13. 13. Volck B, Johansen JS, Stoltenberg M et al. Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology. Osteoarthritis Cartilage 2001; 9: 203–14.
14. 14. Matsumoto T, Tsurumoto T. Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laborarory parameters. Clin Exp Rheumatol 2001: 19; 655–60.
15. 15. Vind I, Johansen, JS, Price PA, Munkholm P. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand J Gastroenterol 2003; 38: 599–605.
16. 16. Koutroubakis IE, Petinaki E, Dimoulios P, Vardas E, Roussomoustakaki M, Maniatis AN, et al. Increased serum levels of YKL-40 in patients with inflammatory bowel disease. Int J Colorectal Dis 2003; 18: 254–59.
17. 17. Kronborg G, Ostergaard C, Weis N et al. Serum level of YKL-40 is elevated in patients with Streptococcus pneumoniae bacteremia and is associated with the outcome of the disease. Scand J Infect Dis 2002; 34: 323–26.
18. 18. Hattori N, Oda S, Sadahiro T et al. YKL-40 identified by proteomic analysis as a biomarker of sepsis. Shock 2009; 32: 393–400.
19. 19. Ostergaard C, Johansen JS, Benfield T, Pric PA, Lundgren JD. YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis. Clin Diagn Lab Immunol 2002; 9: 598–604.
20. 20. Gorvel JP, Moreno E. Brucella intracellular life: from invasion to intracellular replication. Vet Microbiol 2002; 90: 281–97.
21. 21. Fernandes DM, Baldwin CL. Interleukin-10 downregulates protective immunity to Brucella abortus. Infect Immun 1995; 63: 1130–33.
22. 22. Xavier MN, Winter MG, Spees AM et al. CD4+ T cell-derived IL-10 promotes Brucella abortus persistence via modulation of macrophage function. PLOS Pathog 2013; 9: 1003454.
23. 23. Volck B, Price PA, Johansen JS et al. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 1998; 110: 351–60.
24. 24. Johansen JS, Møller S, Price PA et al. Plasma YKL-40: a new potential marker of fibrosis in patients with alcoholic cirrhosis? Scand J Gastroenterol 1997; 32: 582–90.
25. 25. Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 1993; 268: 25803–10.
26. 26. Kirkpatrick RB, Emery JG, Connor JR, Dodds R, Lysko PG, Rosenberg M. Induction and expression of human cartilage glycoprotein 39 in rheumatoid inflammatory and peripheral blood monocyte-derived macrophages. Exp Cell Res 1997; 237: 46–54.
27. 27. Bozdemir ŞE, Altıntop YA, Uytun S, Aslaner H, Torun YA. Diagnostic role of mean platelet volume and neutrophil to lymphocyte ratio in childhood brucellosis. Korean J Intern Med 2017; 32: 1075-81.